来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置首页>技术资料首页>行业动态>融资信息>lonza收购Octane

lonza收购Octane

lonza2019年1月4日 1:44 点击:3906

2018年10月29日 lonza收购Octane

瑞士CDMO巨头Lonza与Octane Biotech合作开发自动生物反应器Cocoon™,这是一个由多个一体化单元组成的高通量系统,可以通过可定制规模的高通量方式并行处理源细胞,被称为GMP-in-a-box系统。


Lonza Acquires a Controlling Stake in Octane Biotech to Further Develop Cocoon TM Autologous Technology

October 29,2018

  • Acquisition further strengthens Lonza’s commitment to drive the next generation of manufacturing patient-specific and personalized therapies

Basel, Switzerland, 29 October 2018 – Lonza announced today the acquisition of a controlling stake in Octane Biotech, with the right to acquire full ownership. The increase in equity share will allow Lonza to further develop the technology to support the growing need for scalable autologous manufacturing. Octane Orthobiologics Inc. will maintain exclusivity to a certain subset of orthopedic clinical indications for use in the CocoonTM system. 

The two companies have been collaborating since 2015 on the development of the Cocoon™ system, a patient-scale, closed and automated cell-therapy manufacturing system.

Following an intensive joint-development program, the CocoonTM system now incorporates the majority of unit operations needed for scalable end-to-end manufacturing of cell therapies including Mesenchymal stem cells (MSC) and Chimeric Antigen Receptor T cells (CAR-T cells).

In addition, the flexible, disposable cassettes can be modified to accommodate a wide range of autologous cell therapy processes for adherent cells, non-adherent cells and combination products. This advantage provides flexibility in a field that utilizes a variety of cell types and processes.

CocoonTM also aims to answer some of the key challenges facing autologous cell therapies as they reach the commercial stage, including variability in cell yields and the stringent regulations in place once products are registered. Automating autologous cell therapy manufacturing in a closed system enables superior process control, leading to fewer deviations and higher cell quality.

“This acquisition is a clear message to the market that we are committed to making commercially viable and scalable personalized therapies a reality,” said Marc Funk, COO of Lonza Pharma & Biotech. “We are looking to disruptive innovation, including automation to enable our customers to bring these promising therapies to patients.”

Timothy Smith, co-founder of Octane Biotech with Ian Grant, said, “As continuing shareholders and directors of Octane Biotech, we welcome the expanded engagement of Lonza to significantly accelerate and reinforce the role of the CocoonTM system as a game changer in the autologous cell therapy manufacturing space. Since the inception of the company, the vision of our team has been to bring award-winning innovation to this sector, and we are confident that Lonza will excel in enabling these transformative therapies to reach more patients throughout the world.”

The CocoonTM system is part of Lonza’s array of autologous cell therapy offerings. The company is currently working with a number of customers, with therapies in various clinical stages, to integrate the CocoonTMmanufacturing equipment as a key part of their clinical and commercial manufacturing strategy.

Octane Biotech’s 24 employees at the current site in Kingston, ON (CA) will continue to support activities as the CocoonTM system is further developed. In addition, the Lonza autologous cell therapy R&D group will maintain their complete support of CocoonTM system-related activities from their Maryland (USA) R&D site.

More information about CocoonTM and Lonza’s offering in cell & gene therapy can be found here.


(来源: lonza )


全年征稿 / 资讯合作

联系邮箱:kefu@labbase.net

版权与免责声明

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://www.labbase.net,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。